Understanding how beta-lactam antibiotics work in patients with infective endocarditis
Betalactam Pharmacokinetics in Endocarditis Patients
This study is trying to see how beta-lactam antibiotics work in patients with infective endocarditis and how different factors like age and weight might affect their effectiveness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Uppsala University Academic / other |
| Locations | 4 sites (Gothenburg and 3 other locations) |
| Trial ID | NCT04647331 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the pharmacokinetics of beta-lactam antibiotics in patients diagnosed with infective endocarditis. It will collect data on antibiotic concentrations, patient characteristics, and treatment outcomes to understand how factors like age, body weight, and renal function influence drug behavior in the body. A mathematical model will be developed to identify which patient factors affect drug pharmacokinetics, potentially leading to improved treatment strategies. The study will involve prospective inclusion of patients from multiple university hospitals in Sweden.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with probable or verified infective endocarditis who are receiving treatment with specific beta-lactam antibiotics.
Not a fit: Patients under 18 years of age or those undergoing hemodialysis are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective antibiotic treatments for patients with infective endocarditis.
How similar studies have performed: Previous research using similar methodologies has shown promise, indicating that this approach is grounded in established scientific inquiry.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Verified or suspected left or right sided endocarditis in native or prosthetic valve * Intravenous antibiotic therapy with either ampicillin, penicillin G, cefotaxime or cloxacillin * Signed informed consent to participate in study Exclusion Criteria: * \<18 years of age * Ongoing dialysis
Where this trial is running
Gothenburg and 3 other locations
- Sahlgrenska University Hospital — Gothenburg, Sweden (Active_not_recruiting)
- Skåne University Hospital — Lund, Sweden (Recruiting)
- Karolinska University Hospital — Stockholm, Sweden (Not_yet_recruiting)
- Uppsala University Hospital — Uppsala, Sweden (Recruiting)
Study contacts
- Principal investigator: Thomas Tängdén, MD, Phd — Uppsala University Hospital
- Study coordinator: Thomas Tängdén, MD, Phd
- Email: thomas.grenholm.tangden@medsci.uu.se
- Phone: +46708370323
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.